Market Closed - Nasdaq Copenhagen 10:59:42 2024-04-26 am EDT 5-day change 1st Jan Change
286.6 DKK +1.49% Intraday chart for ChemoMetec A/S +0.49% -26.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chemometec A/S Reports Revenue for the Third Quarter and First Nine Months of 2023 -2024 CI
ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 CI
ChemoMetec Appoints COO as New CEO MT
ChemoMetec A/S Announces CEO Changes CI
Transcript : ChemoMetec A/S, H1 2024 Earnings Call, Feb 06, 2024
ChemoMetec A/S Maintains Earnings Guidance for the Year 2024 CI
ChemoMetec A/S Reports Earnings Results for the Half Year Ended December 31, 2023 CI
ChemoMetec A/S Announces Executive Changes CI
Transcript : ChemoMetec A/S, 2023 Earnings Call, Sep 14, 2023
ChemoMetec A/S Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Chemometec A/S Proposes Dividend for the 2022/23 Financial Year CI
Chemometec A/S Provides Earnings Guidance for the 2023-2024 Financial Year CI
ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023 CI
ChemoMetec A/S Appoints Rasmus Kofoed as CEO, Effective No Later Than 1 August 2023 CI
ChemoMetec A/S Reports Earnings Results for the Half Year Ended December 31, 2022 CI
ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023 CI
Chemometec A/S Announces Resignation of Steen Søndergaard as CEO CI
ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23 CI
ChemoMetec A/S Reports Earnings Results for the Full Year Ended June 30, 2022 CI
ChemoMetec A/S Reports Earnings Results for the Full Year Ended June 30, 2022 CI
ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023 CI
ChemoMetec A/S Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Chemometec A/S Reaffirms Earnings Guidance for the Financial Year 2021-2022 CI
ChemoMetec Appoints Bent Faurskov as New CFO from 1 October 2021 CI
Chemometec A/S Announces Unaudited Consolidated Earnings Results for the First Half Ended December 31, 2020 CI
Chart ChemoMetec A/S
More charts
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
286.6 DKK
Average target price
462.5 DKK
Spread / Average Target
+61.37%
Consensus